{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:26:51Z","timestamp":1789244811856,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,12]],"date-time":"2015-03-12T00:00:00Z","timestamp":1426118400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ejpn-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.ejpn.2015.02.008","type":"journal-article","created":{"date-parts":[[2015,3,5]],"date-time":"2015-03-05T04:52:39Z","timestamp":1425531159000},"page":"435-445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"title":["Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in\u00a0three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study"],"prefix":"10.1016","volume":"19","author":[{"given":"William","family":"Rosenfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Conry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieven","family":"Lagae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guntis","family":"Rozentals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haichen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randi","family":"Fain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Laurenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpn.2015.02.008_bib1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.spen.2011.06.001","article-title":"Intractable childhood epilepsy: choosing between the treatments","volume":"18","author":"Kossoff","year":"2011","journal-title":"Semin Pediatr Neurol"},{"key":"10.1016\/j.ejpn.2015.02.008_bib2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1517\/14656566.2010.517194","article-title":"Pharmacotherapy for children and adolescents with epilepsy","volume":"12","author":"Verrotti","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ejpn.2015.02.008_bib3","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.seizure.2010.10.027","article-title":"Antiepileptic drug therapy the story so far","volume":"19","author":"Brodie","year":"2010","journal-title":"Seizure"},{"key":"10.1016\/j.ejpn.2015.02.008_bib4","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2015.02.008_bib5","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejpn.2015.02.008_bib6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1054\/jocn.1999.0190","article-title":"Significant anticonvulsant side-effects in children and adolescents","volume":"7","author":"Harbord","year":"2000","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.ejpn.2015.02.008_bib7","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/j.1528-1167.2011.03109.x","article-title":"Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy","volume":"52","author":"Hanada","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2015.02.008_bib8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.5698\/1535-7511-11.2.56","article-title":"Revisiting AMPA receptors as an antiepileptic drug target","volume":"11","author":"Rogawski","year":"2011","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.ejpn.2015.02.008_bib9","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1517\/14656566.2013.754883","article-title":"Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures","volume":"14","author":"Rektor","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ejpn.2015.02.008_bib10","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","article-title":"Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304","volume":"79","author":"French","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2015.02.008_bib11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1528-1167.2012.03638.x","article-title":"Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305","volume":"54","author":"French","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2015.02.008_bib12","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","article-title":"Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures","volume":"78","author":"Krauss","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2015.02.008_bib13","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1528-1167.2012.03648.x","article-title":"Perampanel, a selective, noncompetitive \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307","volume":"54","author":"Krauss","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2015.02.008_bib14","first-page":"263","article-title":"Perampanel study 207: long-term open-label evaluation in patients with epilepsy","volume":"126","author":"Rektor","year":"2012","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.ejpn.2015.02.008_bib15","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/epi.12212","article-title":"Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies","volume":"54","author":"Steinhoff","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2015.02.008_bib16","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/epi.12643","article-title":"Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307","volume":"55","author":"Krauss","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2015.02.008_bib17","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1528-1157.1981.tb06159.x","article-title":"Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League against Epilepsy","volume":"22","year":"1981","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2015.02.008_bib18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.phrs.2012.12.006","article-title":"Novel treatment options for epilepsy: focus on perampanel","volume":"70","author":"Franco","year":"2013","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ejpn.2015.02.008_bib19","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2125.2005.02529.x","article-title":"Clinically relevant drug interactions with antiepileptic drugs","volume":"61","author":"Perucca","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ejpn.2015.02.008_bib20","series-title":"Presented at the 64th annual meeting of the American Academy of Neurology","article-title":"Demographic factors and concomitant antiepileptic drugs have no effect on the pharmacodynamics of perampanel","author":"Hussein","year":"2012"},{"key":"10.1016\/j.ejpn.2015.02.008_bib21","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/01.WNL.0000123695.22623.32","volume":"62","author":"French","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2015.02.008_bib22","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1177\/08830738060210110501","article-title":"Behavioral and emotional problems in children with epilepsy","volume":"21","author":"Freilinger","year":"2006","journal-title":"J Child Neurol"},{"key":"10.1016\/j.ejpn.2015.02.008_bib23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1177\/0883073811417183","article-title":"A long-term open-label extension study assessing cognition and behavior, tolerability, safety, and efficacy of adjunctive levetiracetam in children aged 4 to 16 years with partial-onset seizures","volume":"27","author":"Schiemann-Delgado","year":"2012","journal-title":"J Child Neurol"},{"key":"10.1016\/j.ejpn.2015.02.008_bib24","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.yebeh.2008.05.012","article-title":"Positive and negative psychotropic effects of levetiracetam","volume":"13","author":"Helmstaedter","year":"2008","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ejpn.2015.02.008_bib25","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1111\/j.1528-1167.2009.02197.x","article-title":"Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebo-controlled, noninferiority trial","volume":"50","author":"Levisohn","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2015.02.008_bib26","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1046\/j.1440-1754.2003.00180.x","article-title":"Tolerability of topiramate in children and adolescents","volume":"39","author":"Reith","year":"2003","journal-title":"J Paediatr Child Health"},{"key":"10.1016\/j.ejpn.2015.02.008_bib27","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/11316250-000000000-00000","article-title":"Levetiracetam in childhood epilepsy","volume":"12","author":"Verrotti","year":"2010","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.ejpn.2015.02.008_bib28","series-title":"FYCOMPA (perampanel) US prescribing information","year":"2014"},{"key":"10.1016\/j.ejpn.2015.02.008_bib29","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2147\/NDT.S30129","article-title":"Profile of perampanel and its potential in the treatment of partial onset seizures","volume":"9","author":"Rheims","year":"2013","journal-title":"Neuropsychiatr Dis Treat"}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379815000422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379815000422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T17:26:44Z","timestamp":1537810004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379815000422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S1090379815000422"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2015.02.008","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in\u00a0three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2015.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}